Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has received a medical device license issued by Health Canada and CE Mark from DEKRA Certification B.V. to market Venus Epileve. It is intended as a treatment for hirsutism, permanent hair reduction and pseudofolliculitis barbae in Europe, and for hair removal, permanent hair reduction, and the treatment of pseudofolliculitis barbae in Canada. Venus Epileve represents a new product introduction that expands the Company’s diode laser hair removal offering beyond the Venus Velocity which was introduced to the medical aesthetics market in 2017.

Venus Concept Inc. (“Venus Concept” or the “Company”) (VERO), a global medical aesthetic technology leader, today announced that it has received CE Mark approval to market Venus Bliss for non-invasive lipolysis of the abdomen and flanks, skin tightening, circumferential reduction and cellulite reduction and a medical device license issued by Health Canada to market NeoGraft 2.0 for hair restoration. Venus Bliss is a non-invasive medical aesthetic device that offers a comprehensive solution to fat reduction and cellulite reduction with two technologies in one system.

Chardan Heathcare Acquisition Corp. (CHAC) related to its combination with BiomX Ltd. Pursuant to the terms of the Merger Agreement, BiomX's securityholders will receive an aggregate of 16,625,000 Chardan shares. As a result of the Proposed Transaction, Chardan's public stockholders will only own approximately 20% of Chardan's stock. Click here for more information: https://www.monteverdelaw.com/case/chardan-healthcare-acquisition-corp.  It is free and there is no cost or obligation to you. Restoration Robotics, Inc (HAIR) related to its combination with Venus Concept Ltd. Pursuant to the terms of the Merger Agreement, each share of Venus Concept will be converted into the right to receive 8.6506 shares of Restoration Robotics common stock.

Venus Concept Inc. (“Venus Concept” or the “Company”) (VERO), a global medical aesthetic technology leader, today announced that it has received a CE Mark from DEKRA Certification B.V. and Therapeutic Goods Administration (TGA) clearance in Australia to market NeoGraft 2.0 for hair restoration. NeoGraft 2.0 is intended as an automated hair transplant device using the Follicular Unit Extraction (FUE) method of harvesting and implanting hair follicles. With the introduction of NeoGraft 2.0, Venus Concept has eliminated the inefficiencies of manual extractions and implants and replaced it with advanced technology that provides patients with the benefits of the FUE procedure, while also enabling physicians to benefit from easier transplants that yield superior clinical results.

This regulatory approval is expected to strengthen Restoration Robotics' (HAIR) hair restoration business and expand its presence globally.

SAN JOSE, Calif., Aug. 20, 2019 -- Restoration Robotics, Inc. (NASDAQ:HAIR)(“Restoration Robotics”), a global leader in robotic hair restoration, today announced that Dr..

Restoration Robotics, Inc. (HAIR) (“Restoration Robotics”), a global leader in robotic hair restoration, today announced the voting results for the nine proposals considered and voted upon by its stockholders at its Annual Meeting on October 4, 2019. The Company reported that the various proposals giving effect to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into between Restoration Robotics, Venus Concept Ltd., and Radiant Merger Sub Ltd., dated as of March 15, 2019, as amended on August 14, 2019, were approved by approximately 85% of the outstanding shares of Restoration Robotics.

Restoration Robotics, Inc. (HAIR) (“Restoration Robotics”), a global leader in robotic hair restoration, and Venus Concept Ltd. (“Venus Concept”), a privately-held global medical aesthetic technology leader, today announced that Restoration Robotics has filed definitive proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with the pending merger of Restoration Robotics and Venus Concept. The definitive proxy statement is available on the Investor Relations section of Restoration Robotics’ website, as well as www.sec.gov.

TORONTO, Aug. 16, 2019 /PRNewswire/ -- Venus Concept Ltd. ("Venus Concept"), a privately-held global medical aesthetic technology leader, provided unaudited financial results for the second quarter and first six months of 2019. On March 15, 2019, Restoration Robotics, Inc. (HAIR) and Venus Concept announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction.  Revenue guidance for the combined company continues to be expected in the range of $130-135 million for the twelve months ending December 31, 2019.  Venus Concept is a private company and its shares are not publicly traded.  Venus Concept has not historically reported quarterly financial results and financial information provided for Venus Concept second quarter results is preliminary and subject to change and actual reported results could differ from the results set forth herein.

TORONTO, March 03, 2020 -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that it has expanded.

Venus Concept Inc. (“Venus Concept” or the “Company”) (VERO), a global medical aesthetic technology leader, today announced preliminary unaudited revenue results for the three months and twelve months ended December 31, 2019 and introduced revenue guidance expectations for the twelve months ended December 31, 2020. The Company notes that the GAAP revenue results provided give effect to the business combination between Restoration Robotics, Inc. and Venus Concept Ltd., which closed on November 7, 2019. Preliminary total GAAP revenue for the fourth quarter of 2019 is expected to be in the range of $31.3 million to $32.0 million, compared to total GAAP revenue of $28.6 million in fourth quarter 2018, an increase of 9% to 12% year-over-year.

Restoration Robotics (HAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has received a medical device license issued by Health Canada to market Venus Bliss™, a medical aesthetic platform that offers a comprehensive solution to fat reduction and cellulite reduction, with two technologies in one platform. It is intended for use in non-invasive lipolysis of the abdomen and flanks in individuals with a Body Mass Index (BMI) of 30 or less, and is also indicated for use in temporary skin tightening, circumferential reduction, and cellulite reduction.

NEW YORK , Oct. 10, 2019 /PRNewswire/ -- Altria Group, Inc. (MO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that MO conducted insufficient ...

TORONTO, March 10, 2020 -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that fourth quarter and.

TORONTO, Nov. 14, 2019 -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, provided standalone Venus Concept,.

Venus Concept Inc., a global medical aesthetic technology leader today announced the completion of its previously announced merger with Restoration Robotic, Inc. (NASDAQ: HAIR, through November 7, 2019), a leader in robotic hair restoration, effective as of November 7, 2019. Following the completion of the merger, Venus Concept completed a $28 million equity financing by EW Healthcare Partners, HealthQuest Capital, SEDCO Capital and others. The holders of shares of shares of Venus Concept Ltd. capital stock outstanding immediately prior to the merger received 8.6506 shares of Restoration Robotics common stock in exchange for each share of Venus Concept Ltd. ordinary and preferred shares in the merger.

Venus Concept Inc. (“Venus Concept” or the “Company”) (VERO), a global medical aesthetic technology leader, today announced that it entered into a definitive agreement for the sale of shares of its common stock, Series A convertible preferred stock and warrants to purchase common stock in a private placement to a group of investors, including EW Healthcare Partners, HealthQuest Capital and SEDCO Capital. The private placement is expected to result in gross proceeds to the Company of approximately $22.25 million, before deducting placement agent fees and other offering expenses. Pursuant to the terms of the securities purchase agreement, the Company will issue 2,300,000 shares of common stock, 660,000 shares of Series A convertible preferred stock, which are convertible into 6,600,000 shares of common stock, and warrants to purchase 6,675,000 shares of common stock.

Restoration Robotics, Inc. (HAIR), announced today that it received CE Mark approval for the sale of the ARTAS iX™ System with implantation functionality in Europe. The CE Mark approval follows the Company’s receipt of ISO 13485:2016 Certification for ARTAS iX in January 2019. Ryan Rhodes, President and Chief Executive Officer of Restoration Robotics, states, “We are very pleased to announce our receipt of CE mark approval, which further expands our addressable market for ARTAS iX.

Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the District of Delaware, Case No. 1:19-cv-02237, on behalf of public common shareholders of Restoration Robotics, Inc., ("Restoration Robotics" or the "Company") (Nasdaq: HAIR) who held Restoration Robotics securities as of the record date on September 6, 2019 (the "Class Period"), and have been harmed by Restoration Robotics and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to Venus Concept, Inc. ("Venus").